S2209: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

Objective

Clinical Trial Details

Principal Investigator(s)

Xavier Andrade-Gonzalez, MD

Clinical Trial Categories

• Multiple Myeloma

Contact

Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org